When Was Vitrakvi Approved?

On November 26, 2018, the US Food and Drug Administration (FDA) approved larotrectinib (Vitrakvi; Loxo Oncology), the first drug approved for the treatment of adults and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical ...

Is Vitrakvi FDA-approved?

Vitrakvi for solid tumors. Vitrakvi is FDA-approved to treat solid tumors (cancer) that meet the following conditions: The tumors must have genes called neurotrophic receptor tyrosine kinases that have fused together abnormally.

Is larotrectinib FDA-approved?

Larotrectinib was granted accelerated approval on November 26, 2018, for adult and pediatric patients with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory ...